Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab
Introduction The purpose of this study was to evaluate the clinical outcomes of patients with anterior segment neovascularization treated with or without intravitreal bevacizumab. Methods This was a retrospective, comparative case series of 60 patients with anterior segment neovascularization: 30 co...
Gespeichert in:
| Veröffentlicht in: | Advances in therapy 2009-02, Vol.26 (2), p.208-216 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 216 |
|---|---|
| container_issue | 2 |
| container_start_page | 208 |
| container_title | Advances in therapy |
| container_volume | 26 |
| creator | Lupinacci, Alvaro P. C. Calzada, Jorge I. Rafieetery, Mohammad Charles, Steve Netland, Peter A. |
| description | Introduction
The purpose of this study was to evaluate the clinical outcomes of patients with anterior segment neovascularization treated with or without intravitreal bevacizumab.
Methods
This was a retrospective, comparative case series of 60 patients with anterior segment neovascularization: 30 consecutive patients treated with intravitreal bevacizumab and 30 age-, gender-, and race-matched controls treated without bevacizumab.
Results
The mean follow-up time was 9.1±6.3 months in the bevacizumab group and 8.6±6.2 months in the control group (
P
=0.769). At baseline, no significant difference was observed in initial visual acuity, intraocular pressure, gonioscopy, and iris or angle neovascularization (
P
=0.179, 0.432, 0.065, and 0.966, respectively). At the final examination, no significant difference was observed in mean intraocular pressure (
P
=0.464), mean number of glaucoma medications (
P
=1.00), or presence of anterior segment neovascularization (
P
=0.699). Final visual acuity better than 20/60 was achieved in six patients in the bevacizumab group and none in the control group (
P
=0.013). Comparison of linear regressions of baseline and final visual acuity (LogMAR) showed a significant difference between the two groups (
P
=0.040). In the bevacizumab group, 18 patients required glaucoma surgery, whereas 30 patients in the control group required surgery (
P |
| doi_str_mv | 10.1007/s12325-009-0001-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733323787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733323787</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-aa2ae2b14e476de8944b3ebb6b12233ad08bc2970e2cb22a7376a5ad40f2a0353</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaTZpf0AvRbeenEgj2_Iew9J8QCCXFHoTI3k2VbCtrSRvSH59tPVCbzkMA9LzvjAPY9-kOJdC6IskQUFTCbEuI2QlP7CV7NqmKgMf2UroWlagut8n7DSlJyFA6Kb7zE7kGlTddmLF9pvBT97hwMOcXRgp8bDlO8yeppz4s89_OE6Zog-RJ3ocyzOfKOwxuXnA6F8LGiaeI2GmfgkU9LBLI_dTjhj-odzSHp1_nUe0X9inLQ6Jvh73Gft19fNhc1Pd3V_fbi7vKqdqlStEQAIra6p121O3rmuryNrWSgClsBeddbDWgsBZANRKt9hgX4stoFCNOmM_lt5dDH9nStmMPjkaBiw3zMlopRQo3elCyoV0MaQUaWt20Y8YX4wU5mDbLLZNsW0Oto0sme_H9tmO1P9PHPUWABYgla_pkaJ5CnOcysXvtL4Bb5mN5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733323787</pqid></control><display><type>article</type><title>Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Lupinacci, Alvaro P. C. ; Calzada, Jorge I. ; Rafieetery, Mohammad ; Charles, Steve ; Netland, Peter A.</creator><creatorcontrib>Lupinacci, Alvaro P. C. ; Calzada, Jorge I. ; Rafieetery, Mohammad ; Charles, Steve ; Netland, Peter A.</creatorcontrib><description>Introduction
The purpose of this study was to evaluate the clinical outcomes of patients with anterior segment neovascularization treated with or without intravitreal bevacizumab.
Methods
This was a retrospective, comparative case series of 60 patients with anterior segment neovascularization: 30 consecutive patients treated with intravitreal bevacizumab and 30 age-, gender-, and race-matched controls treated without bevacizumab.
Results
The mean follow-up time was 9.1±6.3 months in the bevacizumab group and 8.6±6.2 months in the control group (
P
=0.769). At baseline, no significant difference was observed in initial visual acuity, intraocular pressure, gonioscopy, and iris or angle neovascularization (
P
=0.179, 0.432, 0.065, and 0.966, respectively). At the final examination, no significant difference was observed in mean intraocular pressure (
P
=0.464), mean number of glaucoma medications (
P
=1.00), or presence of anterior segment neovascularization (
P
=0.699). Final visual acuity better than 20/60 was achieved in six patients in the bevacizumab group and none in the control group (
P
=0.013). Comparison of linear regressions of baseline and final visual acuity (LogMAR) showed a significant difference between the two groups (
P
=0.040). In the bevacizumab group, 18 patients required glaucoma surgery, whereas 30 patients in the control group required surgery (
P
<0.001), usually with a glaucoma drainage implant. Both bevacizumab and control patients who presented with closed angles required glaucoma surgery (
P
=1.000).
Conclusions
Treatment of anterior segment neovascularization with intravitreal bevacizumab significantly improves visual outcomes and significantly decreases the need for glaucoma surgery. In patients with closed anterior chamber angle, addition of bevacizumab treatment does not reduce the need for glaucoma surgery.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-009-0001-1</identifier><identifier>PMID: 19234680</identifier><language>eng</language><publisher>Heidelberg: Springer Healthcare Communications</publisher><subject>Aged ; Aged, 80 and over ; Analysis of Variance ; Angiogenesis Inhibitors - pharmacology ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Cardiology ; Chi-Square Distribution ; Endocrinology ; Female ; Glaucoma, Neovascular - diagnosis ; Glaucoma, Neovascular - drug therapy ; Glaucoma, Neovascular - etiology ; Glaucoma, Neovascular - surgery ; Gonioscopy ; Health technology assessment ; Humans ; Injections, Intraocular ; Internal Medicine ; Intraocular Pressure - drug effects ; Iris - blood supply ; Linear Models ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neovascularization, Pathologic - complications ; Neovascularization, Pathologic - drug therapy ; Oncology ; Original Research ; Pharmacology/Toxicology ; Retrospective Studies ; Rheumatology ; Statistics, Nonparametric ; Trabeculectomy - statistics & numerical data ; Treatment Outcome ; Visual Acuity - drug effects</subject><ispartof>Advances in therapy, 2009-02, Vol.26 (2), p.208-216</ispartof><rights>Springer Healthcare Communications 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-aa2ae2b14e476de8944b3ebb6b12233ad08bc2970e2cb22a7376a5ad40f2a0353</citedby><cites>FETCH-LOGICAL-c343t-aa2ae2b14e476de8944b3ebb6b12233ad08bc2970e2cb22a7376a5ad40f2a0353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-009-0001-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-009-0001-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19234680$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lupinacci, Alvaro P. C.</creatorcontrib><creatorcontrib>Calzada, Jorge I.</creatorcontrib><creatorcontrib>Rafieetery, Mohammad</creatorcontrib><creatorcontrib>Charles, Steve</creatorcontrib><creatorcontrib>Netland, Peter A.</creatorcontrib><title>Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab</title><title>Advances in therapy</title><addtitle>Adv Therapy</addtitle><addtitle>Adv Ther</addtitle><description>Introduction
The purpose of this study was to evaluate the clinical outcomes of patients with anterior segment neovascularization treated with or without intravitreal bevacizumab.
Methods
This was a retrospective, comparative case series of 60 patients with anterior segment neovascularization: 30 consecutive patients treated with intravitreal bevacizumab and 30 age-, gender-, and race-matched controls treated without bevacizumab.
Results
The mean follow-up time was 9.1±6.3 months in the bevacizumab group and 8.6±6.2 months in the control group (
P
=0.769). At baseline, no significant difference was observed in initial visual acuity, intraocular pressure, gonioscopy, and iris or angle neovascularization (
P
=0.179, 0.432, 0.065, and 0.966, respectively). At the final examination, no significant difference was observed in mean intraocular pressure (
P
=0.464), mean number of glaucoma medications (
P
=1.00), or presence of anterior segment neovascularization (
P
=0.699). Final visual acuity better than 20/60 was achieved in six patients in the bevacizumab group and none in the control group (
P
=0.013). Comparison of linear regressions of baseline and final visual acuity (LogMAR) showed a significant difference between the two groups (
P
=0.040). In the bevacizumab group, 18 patients required glaucoma surgery, whereas 30 patients in the control group required surgery (
P
<0.001), usually with a glaucoma drainage implant. Both bevacizumab and control patients who presented with closed angles required glaucoma surgery (
P
=1.000).
Conclusions
Treatment of anterior segment neovascularization with intravitreal bevacizumab significantly improves visual outcomes and significantly decreases the need for glaucoma surgery. In patients with closed anterior chamber angle, addition of bevacizumab treatment does not reduce the need for glaucoma surgery.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis of Variance</subject><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Bevacizumab</subject><subject>Cardiology</subject><subject>Chi-Square Distribution</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Glaucoma, Neovascular - diagnosis</subject><subject>Glaucoma, Neovascular - drug therapy</subject><subject>Glaucoma, Neovascular - etiology</subject><subject>Glaucoma, Neovascular - surgery</subject><subject>Gonioscopy</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Injections, Intraocular</subject><subject>Internal Medicine</subject><subject>Intraocular Pressure - drug effects</subject><subject>Iris - blood supply</subject><subject>Linear Models</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neovascularization, Pathologic - complications</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Oncology</subject><subject>Original Research</subject><subject>Pharmacology/Toxicology</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Statistics, Nonparametric</subject><subject>Trabeculectomy - statistics & numerical data</subject><subject>Treatment Outcome</subject><subject>Visual Acuity - drug effects</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVpaTZpf0AvRbeenEgj2_Iew9J8QCCXFHoTI3k2VbCtrSRvSH59tPVCbzkMA9LzvjAPY9-kOJdC6IskQUFTCbEuI2QlP7CV7NqmKgMf2UroWlagut8n7DSlJyFA6Kb7zE7kGlTddmLF9pvBT97hwMOcXRgp8bDlO8yeppz4s89_OE6Zog-RJ3ocyzOfKOwxuXnA6F8LGiaeI2GmfgkU9LBLI_dTjhj-odzSHp1_nUe0X9inLQ6Jvh73Gft19fNhc1Pd3V_fbi7vKqdqlStEQAIra6p121O3rmuryNrWSgClsBeddbDWgsBZANRKt9hgX4stoFCNOmM_lt5dDH9nStmMPjkaBiw3zMlopRQo3elCyoV0MaQUaWt20Y8YX4wU5mDbLLZNsW0Oto0sme_H9tmO1P9PHPUWABYgla_pkaJ5CnOcysXvtL4Bb5mN5Q</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Lupinacci, Alvaro P. C.</creator><creator>Calzada, Jorge I.</creator><creator>Rafieetery, Mohammad</creator><creator>Charles, Steve</creator><creator>Netland, Peter A.</creator><general>Springer Healthcare Communications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090201</creationdate><title>Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab</title><author>Lupinacci, Alvaro P. C. ; Calzada, Jorge I. ; Rafieetery, Mohammad ; Charles, Steve ; Netland, Peter A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-aa2ae2b14e476de8944b3ebb6b12233ad08bc2970e2cb22a7376a5ad40f2a0353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis of Variance</topic><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Bevacizumab</topic><topic>Cardiology</topic><topic>Chi-Square Distribution</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Glaucoma, Neovascular - diagnosis</topic><topic>Glaucoma, Neovascular - drug therapy</topic><topic>Glaucoma, Neovascular - etiology</topic><topic>Glaucoma, Neovascular - surgery</topic><topic>Gonioscopy</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Injections, Intraocular</topic><topic>Internal Medicine</topic><topic>Intraocular Pressure - drug effects</topic><topic>Iris - blood supply</topic><topic>Linear Models</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neovascularization, Pathologic - complications</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Oncology</topic><topic>Original Research</topic><topic>Pharmacology/Toxicology</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Statistics, Nonparametric</topic><topic>Trabeculectomy - statistics & numerical data</topic><topic>Treatment Outcome</topic><topic>Visual Acuity - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lupinacci, Alvaro P. C.</creatorcontrib><creatorcontrib>Calzada, Jorge I.</creatorcontrib><creatorcontrib>Rafieetery, Mohammad</creatorcontrib><creatorcontrib>Charles, Steve</creatorcontrib><creatorcontrib>Netland, Peter A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lupinacci, Alvaro P. C.</au><au>Calzada, Jorge I.</au><au>Rafieetery, Mohammad</au><au>Charles, Steve</au><au>Netland, Peter A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Therapy</stitle><addtitle>Adv Ther</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>26</volume><issue>2</issue><spage>208</spage><epage>216</epage><pages>208-216</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Introduction
The purpose of this study was to evaluate the clinical outcomes of patients with anterior segment neovascularization treated with or without intravitreal bevacizumab.
Methods
This was a retrospective, comparative case series of 60 patients with anterior segment neovascularization: 30 consecutive patients treated with intravitreal bevacizumab and 30 age-, gender-, and race-matched controls treated without bevacizumab.
Results
The mean follow-up time was 9.1±6.3 months in the bevacizumab group and 8.6±6.2 months in the control group (
P
=0.769). At baseline, no significant difference was observed in initial visual acuity, intraocular pressure, gonioscopy, and iris or angle neovascularization (
P
=0.179, 0.432, 0.065, and 0.966, respectively). At the final examination, no significant difference was observed in mean intraocular pressure (
P
=0.464), mean number of glaucoma medications (
P
=1.00), or presence of anterior segment neovascularization (
P
=0.699). Final visual acuity better than 20/60 was achieved in six patients in the bevacizumab group and none in the control group (
P
=0.013). Comparison of linear regressions of baseline and final visual acuity (LogMAR) showed a significant difference between the two groups (
P
=0.040). In the bevacizumab group, 18 patients required glaucoma surgery, whereas 30 patients in the control group required surgery (
P
<0.001), usually with a glaucoma drainage implant. Both bevacizumab and control patients who presented with closed angles required glaucoma surgery (
P
=1.000).
Conclusions
Treatment of anterior segment neovascularization with intravitreal bevacizumab significantly improves visual outcomes and significantly decreases the need for glaucoma surgery. In patients with closed anterior chamber angle, addition of bevacizumab treatment does not reduce the need for glaucoma surgery.</abstract><cop>Heidelberg</cop><pub>Springer Healthcare Communications</pub><pmid>19234680</pmid><doi>10.1007/s12325-009-0001-1</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0741-238X |
| ispartof | Advances in therapy, 2009-02, Vol.26 (2), p.208-216 |
| issn | 0741-238X 1865-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733323787 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Aged, 80 and over Analysis of Variance Angiogenesis Inhibitors - pharmacology Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Cardiology Chi-Square Distribution Endocrinology Female Glaucoma, Neovascular - diagnosis Glaucoma, Neovascular - drug therapy Glaucoma, Neovascular - etiology Glaucoma, Neovascular - surgery Gonioscopy Health technology assessment Humans Injections, Intraocular Internal Medicine Intraocular Pressure - drug effects Iris - blood supply Linear Models Male Medicine Medicine & Public Health Middle Aged Neovascularization, Pathologic - complications Neovascularization, Pathologic - drug therapy Oncology Original Research Pharmacology/Toxicology Retrospective Studies Rheumatology Statistics, Nonparametric Trabeculectomy - statistics & numerical data Treatment Outcome Visual Acuity - drug effects |
| title | Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T06%3A16%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20of%20patients%20with%20anterior%20segment%20neovascularization%20treated%20with%20or%20without%20intraocular%20bevacizumab&rft.jtitle=Advances%20in%20therapy&rft.au=Lupinacci,%20Alvaro%20P.%20C.&rft.date=2009-02-01&rft.volume=26&rft.issue=2&rft.spage=208&rft.epage=216&rft.pages=208-216&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-009-0001-1&rft_dat=%3Cproquest_cross%3E733323787%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733323787&rft_id=info:pmid/19234680&rfr_iscdi=true |